GlassScriptPhysician profile
Emily Q Chen
NPI 1396947503
$6,536.35
in general payments reported to CMS, 2019-2025
51 companies · $1,254 in 2025
The $1,254 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $692 · 2020: $2,466 · 2022: $170 · 2023: $687 · 2024: $1,267 · 2025: $1,254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,834 · Education: $374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,833.95 |
| Education | $374.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $2,623.88 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $386.25 | 2019-2025 | Opdivo, Opdualag, Augtyro |
| Astellas Pharma US INC | $311.22 | 2020-2025 | Padcev, Vyloy |
| Gilead Sciences, INC. | $274.16 | 2019-2025 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $245.78 | 2019-2025 | Calquence, Enhertu, Imfinzi |
| Daiichi Sankyo INC. | $243.21 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Novartis Pharmaceuticals Corporation | $163.00 | 2019-2025 | |
| Lilly USA, LLC | $149.48 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Pfizer INC. | $147.84 | 2019-2025 | |
| Incyte Corporation | $139.55 | 2019-2022 | |
| Genzyme Corporation | $138.18 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $134.73 | 2019-2024 | Keytruda, Lynparza, Welireg |
| Bayer Healthcare Pharmaceuticals INC. | $134.00 | 2019-2025 | |
| Beigene USA, INC. | $123.85 | 2023 | Brukinsa |
| Janssen Biotech, INC. | $106.85 | 2019-2025 | Carvykti, Erleada, Talvey |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.